There is no single best medicine for colon cancer. The right treatment depends on the cancer’s stage, its genetic profile, and specific biomarkers found through tumor testing. Most people with colon cancer receive some combination of chemotherapy, and many also qualify for targeted therapy or immunotherapy based on their tumor’s biology. The overall five-year survival rate for colorectal cancer is now 65.4%, up from about 49% in 1975, largely because of advances in these drug combinations.
Why Tumor Testing Comes First
Before any treatment plan is chosen, your tumor will be tested for specific genetic mutations and biomarkers. This step determines which drugs will actually work for you and which ones won’t. About 60% of people with metastatic colorectal cancer carry a genetic change that predicts a poor response to certain targeted therapies. Without testing, you could end up on a drug that has little chance of helping.
The key markers tested include KRAS, NRAS, and BRAF gene mutations, as well as a feature called microsatellite instability (MSI-H) or mismatch repair deficiency (dMMR), which indicates how well your cells fix their own DNA errors. KRAS and NRAS mutations, found in a large share of patients, rule out a class of targeted drugs that block a growth signal on the surface of cancer cells. BRAF mutations, specifically one called V600E, rule out those same drugs in another 9% of patients. On the flip side, BRAF mutations and HER2-positive status open the door to other targeted treatments designed for those specific tumor types.
Chemotherapy Regimens by Stage
Surgery is the primary treatment for early-stage colon cancer, and many people with stage I disease need no medication afterward. For stage II cancers that have higher-risk features, doctors typically recommend a chemotherapy drug based on fluorouracil (5-FU) or its oral equivalent, capecitabine, sometimes with the addition of oxaliplatin. Stage III colon cancer, where the disease has spread to nearby lymph nodes, almost always calls for chemotherapy after surgery to reduce the chance of recurrence.
The two most common chemotherapy regimens are FOLFOX and CAPOX. FOLFOX combines 5-FU, leucovorin, and oxaliplatin, delivered intravenously every two weeks. It requires a central line (a catheter placed in a large vein) because one component runs as a 46-hour continuous infusion. CAPOX pairs oxaliplatin with capecitabine, an oral pill that replaces the IV fluorouracil. The major advantage of CAPOX is convenience: you take pills at home for two weeks, then have a week off, eliminating the need for a long-term catheter and multi-day infusions.
For metastatic (stage IV) colon cancer, a third regimen called FOLFIRI, which substitutes irinotecan for oxaliplatin, is also widely used. Oncologists often combine these chemotherapy backbones with targeted drugs to improve outcomes.
Oral Versus IV Chemotherapy
A landmark trial published in the New England Journal of Medicine compared oral capecitabine head-to-head with IV fluorouracil plus leucovorin in nearly 2,000 patients with stage III colon cancer. Capecitabine proved at least as effective, with a three-year disease-free survival rate of 64.2% compared to 60.6% for the IV regimen. Capecitabine also caused significantly fewer adverse events overall. For many patients, oral chemotherapy offers equivalent cancer control with less time spent in an infusion chair and fewer complications from IV access.
Targeted Therapy
Targeted drugs attack specific proteins that help cancer cells grow or build new blood vessels. Two broad categories are used in colon cancer. The first blocks a protein called VEGF, which tumors use to recruit blood supply. Bevacizumab is the most established drug in this class and can be combined with chemotherapy regardless of most tumor mutations.
The second category targets a protein called EGFR, a growth signal receptor on the surface of cancer cells. Cetuximab and panitumumab are the two approved drugs in this group. Here is where tumor testing becomes critical: these drugs only work in patients whose tumors have no mutations in the RAS genes (KRAS and NRAS) and no BRAF V600E mutation. If any of those mutations are present, these drugs provide no benefit.
For the roughly 3% of colorectal cancers that are HER2-positive and RAS wild-type (no RAS mutations), the FDA granted accelerated approval in 2023 to a combination of tucatinib and trastuzumab. This pairing targets the HER2 protein directly and is used after standard chemotherapy has stopped working. Tucatinib is taken as a pill twice daily, while trastuzumab is given by IV infusion every three weeks.
Immunotherapy for Specific Tumor Types
Immunotherapy works by helping your immune system recognize and attack cancer cells. In colon cancer, it is effective only in tumors that are microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR), a feature found in roughly 15% of all colon cancers and about 5% of metastatic cases. These tumors accumulate many mutations, making them more visible to the immune system when given a boost.
Pembrolizumab, a drug that blocks a protein called PD-1 on immune cells, was tested against standard chemotherapy as a first-line treatment for metastatic MSI-H/dMMR colorectal cancer in a phase 3 trial of 307 patients published in the New England Journal of Medicine. It produced durable responses, meaning the cancer stayed controlled for extended periods, and has become the preferred first treatment for this group. Nivolumab, another PD-1 blocker, has also shown durable responses in this population. For the roughly 85% of colon cancers that are not MSI-H, immunotherapy alone has limited effectiveness, and chemotherapy-based regimens remain the standard.
Survival Rates by Stage
How well treatment works depends heavily on how far the cancer has spread at diagnosis. Based on data from 2015 to 2021, the five-year relative survival rates for colorectal cancer break down as follows:
- Localized (confined to the colon wall): 91.5%, representing about 34% of cases at diagnosis
- Regional (spread to nearby lymph nodes): 74.6%, representing about 37% of cases
- Distant (metastatic, spread to other organs): 16.2%, representing about 23% of cases
These numbers reflect averages across all patients, including those diagnosed years ago. Newer targeted therapies and immunotherapy combinations continue to push survival rates upward, particularly for metastatic disease, where treatment options have expanded substantially in the last decade.
Common Side Effects of Treatment
Each drug carries its own side effect profile, and your experience will depend on which regimen you receive. Across most chemotherapy combinations, nausea, fatigue, and diarrhea are common. But one side effect deserves special attention because of how often it persists long after treatment ends: nerve damage caused by oxaliplatin.
Oxaliplatin, a component of both FOLFOX and CAPOX, causes chronic nerve damage in up to 50% of patients. Among colorectal cancer survivors who received it, 89% reported at least one symptom of peripheral neuropathy. The most frequent complaint is numbness or tingling in the feet, affecting about 71% of survivors, followed by numbness or tingling in the hands at about 64%. Other symptoms include sensitivity to cold temperatures (56%), weakness in the arms or legs (45%), trouble with balance (44%), and discomfort or pain in the feet (49%) or hands (34%).
These symptoms are not just physical inconveniences. Research shows oxaliplatin-induced neuropathy is linked to increased depressive symptoms, reduced sleep quality, and lower overall quality of life. The severity tends to worsen with cumulative doses, so oncologists monitor nerve symptoms closely during treatment and may reduce the dose or stop oxaliplatin early if neuropathy becomes significant. If you’re on a regimen containing oxaliplatin, reporting tingling or numbness early gives your care team the best chance to adjust before the damage becomes permanent.